牛唐2018-04-19 21:46
$Surface Oncology(SURF)$ 主攻肿瘤微环境的公司,通过微环境的调节,激发细胞自身免疫活性,领头产品是针对cd47靶点的srf231,于今年2月开始临床一期,一旦成功,既可以单独用药,也可以联合用药,且可针对多个适应症。公司和诺华是战略合作关系,股东是清一色知名药企和投资机构:lily,amgen,ne...查看全文
智通财经APP获悉,据媒体消息,专攻免疫疗法的Surface Oncology(SURF.US)公司收到了葛兰素史克(GSK.US)的收购意向。 报道称,除葛兰素史克之外,Surface Oncology还在寻找其它任何可能的收购者。 此前,百时美施贵宝(BMY.US)在同意收... 网页链接
$Surface Oncology(SURF)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-23-236303 Act: 34 Size: 12 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002629 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002628 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-23-231522 Act: 33 Size: 21 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231530 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231534 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231535 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231539 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231542 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231544 Act: 33 Size: 23 KB 网页链接